Rtw Investments, LP Bellus Health Inc. Transaction History

Rtw Investments, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$5.56 - $7.99 $33.2 Million - $47.7 Million	-5,968,017 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.26 - $8.3 $5.26 Million - $8.3 Million	1,000,000 Added 20.13%	5,968,017 $48 Million
Q1 2021 May 14, 2021	SELL	$3.03 - $4.58 $672,190 - $1.02 Million	-221,845 Reduced 4.27%	4,968,017 $19 Million
Q4 2020 Feb 16, 2021	BUY	$2.27 - $3.3 $2.26 Million - $3.28 Million	994,506 Added 23.7%	5,189,862 $15.8 Million
Q3 2020 Nov 16, 2020	SELL	$2.14 - $12.02 $3.8 Million - $21.3 Million	-1,774,874 Reduced 29.73%	4,195,356 $9.55 Million
Q2 2020 Aug 14, 2020	BUY	$8.88 - $11.15 $4.26 Million - $5.34 Million	479,238 Added 8.73%	5,970,230 $61.6 Million
Q1 2020 May 15, 2020	BUY	$5.77 - $10.85 $3.75 Million - $7.05 Million	650,000 Added 13.43%	5,490,992 $54.8 Million
Q4 2019 Feb 14, 2020	BUY	$5.76 - $7.6 $3.82 Million - $5.04 Million	662,836 Added 15.86%	4,840,992 $36.6 Million
Q3 2019 Nov 14, 2019	BUY	$6.24 - $8.84 $26.1 Million - $36.9 Million	4,178,156 New	4,178,156 $26.9 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Rtw Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Rtw Investments, LP with notifications on news.